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Abstract Developments in genetics are rapidly changing the
capacity and scope of screening practices. However, people
with genetic conditions have been under-represented in the
literature exploring their implications. This mixed methods
study explores the attitudes of people with Spinal Muscular
Atrophy (SMA) towards three different population-level ge-
netic screening programmes for SMA: pre-conception, prena-
tal and newborn screening. Drawing on qualitative interviews
(n = 15) and a survey (n = 82), this study demonstrates that
more severely affected individuals with early-onset symptoms
(Type II SMA), are less likely to support screening and more
likely to view SMA positively than those with milder, later
onset and/or fluctuating symptoms (Types III/ IV SMA).
Indeed, this clinically milder group were more likely to sup-
port all forms of screening and view SMA negatively. This
paper highlights that screening is a complex issue for people
with genetic conditions, and the nature of impairment experi-
ences plays a critical role in shaping attitudes.
Keywords Spinal muscular atrophy . Genetics screening .
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Introduction
As reprogenetic medicine advances, and technologies such as
whole genome sequencing and Non-Invasive Prenatal Testing
(NIPT) are increasingly becoming part of mainstream NHS
healthcare (Genomics England 2012; Wells et al. 2014; UK
National Screening Committee 2013), important social and
ethical questions emerge around their usage. Chief among
these concerns is the question of which conditions the tech-
nologies can justifiably be employed to prevent, particularly
as the number of genetic disorders that it is possible to detect
through these means is rapidly burgeoning (Plantinga et al.
2016; Leo et al. 2016).
People currently living with the genetic conditions that are
potential candidates for such population screening have much to
contribute to answering these questions. However, their perspec-
tives have been vastly under-explored in the literature (Allyse
et al. 2015; Barter et al. 2016; Nuffield Council on Bioethics
2017). Indeed, the literature around expanded genetic screening
has instead largely focused on the intended administers and re-
cipients of such screening; the general public (Pei-Jung et al.
2017; Plantinga et al. 2016), new/expectant parents (Norton
et al. 2014; Green et al. 1993) and/or health care professionals
(Watson et al. 1991). This oversight is striking given the potential
for substantial impacts on people with genetic disabilities should
screening be introduced. These impacts might include: changes
in the public profile of the disease they live with, emotional harm
associated with having a condition that wider society seeks to
avoid (Boardman 2014; Barter et al. 2016) reduced public
funding for biomedical research into treatments for the condition
(asscciated with declining numbers of people born with the con-
dition), as well as reductions in the availability of peer and com-
munity support (Nuffield Council on Bioethics 2017).
Where the views of adults with genetic disabilities towards
screening and testing have been explored, conclusions have
been somewhat contradictory, with some studies revealing reti-
cence, ambivalence and even active hostility towards screening
(e.g. Barter et al. 2016; Benjamin et al. 1993; Middleton et al.
1998; Stern et al. 2002) and others revealing far more supportive
* Felicity K. Boardman
felicity.boardman@warwick.ac.uk
1 Division of Health Sciences, Warwick Medical School, University of
Warwick, Coventry, UK
2 School of Life Sciences, University of Warwick, Coventry, UK
J Genet Counsel
DOI 10.1007/s10897-017-0122-7
and accepting attitudes (Chen and Schiffman 2000). This strong
diversity of views is perhaps unsurprising given the heterogene-
ity of adults with genetic disabilities, both in terms of the nature
of their conditions, but also in terms of the way(s) they are
experienced in everyday life. In spite of this, however, the rela-
tionship between the nature of a person’s impairment, and their
attitudes towards screening has remained under-explored within
the literature. Indeed, this has persisted despite the widespread
acknowledgement that everyday experiences are critical to un-
derstanding the varying attitudes towards treatment and cure
amongst different impairment groups (Shakespeare 2006;
Bogart 2014; Bogart et al. 2012; Hahn and Belt 2004).
This study, using mixed methods research techniques, ad-
dresses this gap in the literature by exploring attitudes towards
genetic screening amongst people diagnosed with a condition
for which population screening could feasibly soon be offered,
Spinal Muscular Atrophy (SMA).
Spinal Muscular Atrophy (SMA) and Population Level
Genetic Screening
Spinal muscular atrophy is an autosomal recessive neuromus-
cular disorder that has been described as the most common
genetic cause of infant death (Butchbatch 2016). As such, it is
has been argued that it is a prime candidate for inclusion in
expanded genetic screening programmes (Prior 2010). Indeed,
the recent FDA approval of nusinersen as a treatment for SMA
has re-kindled calls for newborn screening programmes to be
introduced in the United States and beyond (Ottesen 2017).
SMA is sub-classified into four main types, based on age of
onset and severity, although the boundaries of these classifica-
tions are contested (Dubowitz 1991). Type I SMA is the severest
form, with onset within the first few months of life and death
usually occurring before 18 months. Type II SMA
(intermediate) is the most divergent form, with onset usually
within the first two years of life.With improved support, lifespan
for people with SMAType II can remain near-normal, although
such indviduals remain vulnerable to respiratory infections and
complications throughout their lives, which may lead to prema-
ture death. Type III SMA is usually diagnosed after the age of
4 years, with the majority of those affected able to sit and stand
unaided. Type IV SMA is diagnosed in adulthood, with patients
developing generalised muscle weakness. In both Types III and
IV there is a gradual deterioration of abilities over time, although
life span is usually unaffected (Wang et al. 2007).
All four sub-types are caused by functional loss of the
Survival Motor Neuron1 (SMN1) gene, with the clinical severity
of the disease believed to be (at least in part) regulated by the
copy number of a second SMN gene, SMN2. As current genetic
analysis can detect SMN1 deletions and assess SMN2 copy num-
ber, they have the potential to accurately sub-type at diagnosis
(as confirmed by several small pilot studies in the US).
However, as there has been no longitudinal large scale trial,
the sensitivity and specificity of a SMN1 / SMN2 prognostic
and diagnostic algorithm is unknown. As a result, there is a wide
variety of SMA screening practices in the international arena. In
the UK, although prenatal testing and cascade carrier screening
are routinely offered to families with a known history of SMA,
there is currently no screening programme in place for the gen-
eral population (UK National Screening Committee 2013;
ACOG, 2009; Cartwright 2012). In comparison, some countries
have implemented compulsory pre-martial SMA carrier screen-
ing programmes (e.g. Qatar) and Israel and Australia offer
screening through state-sponsored health care plans (Sukenik-
Halevy et al. 2012). In the United States, SMA is currently being
considered for inclusion on the state-wide newborn screening
panel. It seems reasonable, therefore, to assme that popualtion
screening for SMA could one day feasibly be offered within the
UK, particularly in the context of emerging therapies.
This study, using mixed methods research techniques, ex-
plores attitudes towards genetic screening amongst people di-
agnosed with SMA. As SMA can present as an adult-onset,
childhood onset or congenital impairment (with vastly
contrasting levels of severity within these sub-types) a focus
on SMA as a candidate genetic screening condition allows an
analysis across a broad range of impairment experiences,
while maintaining a meaningful comparison between them,
within the broad remit of neuromuscular impairment. By so-
doing, this study makes an important contribution to an un-
derstanding of the views of people with genetic disabilities in
an age of expanding genomic medicine.
Methods
The data reported in this study are derived from a larger study
of attitudes towards screening for SMA amongst both adults
with SMA and their family members, the findings of which
are reported elsewhere (Boardman et al. 2017). While family
members are an important stakeholder group in debates
around genetic screening in their own right, people with ge-
netic conditions have unique experiential knowledge of the
condition in question and are set to affected by population
genetic screening in very specific ways (Chen and
Schiffman 2000; Allyse et al. 2015). Therefore, the views of
this group of adults was considered worthy of a separate and
focused analysis. An exploratory sequential mixed methods
research design was adopted, and the research took place in
three distinct phases.
Within all phases, participants were asked about three po-
tential screening programmes for SMA:
1. A pre-conception screening programme (whereby
members of the general population are offered screening
for their SMA carrier status before conceiving a
pregnancy)
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2. A prenatal screening programme (whereby pregnant
women and their partners are offered screening for carriers
status, and the foetus tested for SMAwhere indicated)
3. A newborn screening programme (whereby parents of
newborn babies are offered genetic screening to determine
whether the baby has SMA).
Phase I: Qualitative Interviews
In-depth qualitative interviews were undertaken with 36 people
who either had SMA or had a diagnosis of SMA in their family.
These participants were recruited through advertisements placed
in the publications of the main support and advocacy group for
families living with SMA in the UK, ‘SMA Support UK’.
Fifteen interviews were conducted with adults with SMA, and
21 with family members of people with SMA (see Table 1 for
breakdown of participants). For the purposes of this study, only
the 15 interviewswith affected adults were included for analysis.
Interviews were designed to explore experiences with SMA,
views around/uses of genetic testing technologies and selective
termination, as well as perceptions of the possible introduction
of population screening for SMA. Participants were eligible for
interview if they were aged 18 or over, English speaking and
either had SMA themselves, or had at least one diagnosis of
SMA in their family. Pregnant women were excluded from the
study due to the increased sensitivity of the topic area.
Data were analysed using Nvivo 10 software by an experi-
enced researcher under the supervision of two senior aca-
demics who provided feedback on the developing coding
framework. A constructivist approach to grounded theory data
analysis was used (Charmaz 2008). This process was induc-
tive, allowing the themes to emerge directly from the data,
although unlike traditional grounded theory approaches, the
literature was consulted during the data analysis to facilitate
refinement. After the initial ‘open coding’ of the data, higher
level hierarchical coding was undertaken. A process of coding,
refinement of concepts (through data interpretation and con-
sultation with the literature) and re-coding was carried out over
a period of five months until ‘saturation’ had occured (i.e. no
new concepts were emerging and all of the data were incorpo-
rated within the coding framework) (Glaser and Strauss 1967).
Phase II: SMA Screening Survey (UK)
Following completion of the qualitative analysis, a survey- the
SMA Screening Survey (UK)- was developed in order to
gauge attitudes across a wider population of families living
with SMA. Details of the development of the SMA Screening
Survey (UK) have been presented more fully elsewhere
(Boardman et al. 2017). In brief, the overarching themes from
the qualitative analysis were used to develop both the key
domains, but also the individual questions within the survey.
Questions that were included to capture demographic infor-
mation (e.g. religious faith/ethnicity) were either directly rep-
licated from, or appear as modified versions of, questions
from the 2011 UK Census survey.
The SMA Screening Survey (UK) contained 22 items.
Questions pertaining to views on screening took the form of
an attitude statement derived direclty from the qualitative
analysis (for example, ‘It would be a loss to society to have
less people with SMA coming into the world’) presented in
conjunction with a lickert scale. Cognitive interviewing was
undertaken with six people with experience of SMA to ex-
plore the mental processes that participants used to answer the
survey questions (Willis 2005). In addition to the cognitive
interviews, the survey was independently reviewed by two
expert panels (one professional, one made up of people living
with SMA and their families) and the survey questions were
further developed in line with their feedback.
Phase II data collection was carried out over a period of ten
months, September 2014–June 2015. Two versions of the sur-
vey were made available, an online version (hosted on a se-
cure website) and a paper version. The paper version was
posted to all members of SMA Support UK (1500 house-
holds) in September 2014 and participants were encouraged
to distribute it within their networks of friends and family
affected by SMA. Potential participants were invited to com-
plete the survey if they were over 18, had not taken part in a
Phase I interview and either had SMA themselves, or had at
least one diagnosis of SMA in the family.
Demographic variables were stratified as follows: 1)
Gender (male (1) v female (0)); 2) Highest qualification
(> = degree (1) v < degree (0)); 3) Religious (any) (yes (1) v
no (0)); 4) Do you have children (own, fostered or adopted)
(yes (1) v no (0)); 5) How do you rate your current health
(good (1) v not good (0)); and 6) Are you currently trying to
conceive (yes (1) v no (0)). For all questions relating to views
on SMA or screening programmes, responses were stratified
into two groups: 1) BAgree^ which contain strongly agree and
agree responses; and 2) BOther^ which contained disagree,
strongly disagree and neither agree nor disagree responses.
Demographic impacts on responses were assessed using
logistic regression analysis; when interpreting the results pos-
itive drivers were indicated by an odds ratio > 1; negative
drivers were indicated by an odds ratio < 1 (for logistic
Table 1 Qualitative interview participants
Type of SMA Gender Age Total
Male Female 18–35 36–50 51+
Type II SMA 3 5 4 3 1 8
Type III SMA 1 4 0 4 1 5
Type IV SMA 1 1 0 1 1 2
Totals 5 10 5 8 3 15
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regression to cut off for significance was set at p < = 0.05).
The demographic responses were stratified as binominal var-
iables (as highlighted above) to allow analysis using
binominal univariate logistic regression (SPSS software v22,
IBM).
The attitudes of adults with SMA on the disease itself and
the three proposed screening programmes (pre-conception
genetic screening, prenatal screening and newborn
screening) were compared to determine if there were any sta-
tistical differences. Responses from adults with Types II, III
and IV were compared. The individual questions were
assessed and then responses correlated against support for
screening. For each question the number of Bagree’ v Bother^
responses were reported and statistical differences between
distribution of responses for the adults with the different sub-
types were assessed using a chi-squared analysis (Graphpad
Prism software, v6).
Phase III: Re-Interrogation of Qualitative Data
Key findings that emerged as significant from the quantitative
analysis were explored further within the qualitative data in
Phase III of the study. Returning to the qualitative data in an
exploratory sequential mixed methods research design has
been identified as a research technique particularly useful in
drawing out the nuances, complexities and contradictions in
participants’ views that would otherwise be missed by
monomethod research (Plano Clark and Creswell 2008).
Excerpts from the qualitative data were selected for inclusion
in this paper if they particularly eloquently communicated or
clarified a key finding. All of the qualitative findings reported
in this paper are derived from Phase III analysis. Pseudonyms
have been used throughout, and all identifying information
was removed at the point of transcription in order to
safeguard- as far as possible- the anonymity of participants.
Results
Quantitative Results
Cohort Characteristics
Eighty-two adults with SMA responded to the SMA survey:
27 (33%) with Type II SMA; 31 (38%) with Type III SMA;
and 24 (29%) with Type IV SMA. In all, the majority of
responders were female (55%), did not have an undergraduate
degree (66%), were religious (55%), were parents (either
adopted, fostered or their own) (51%), did not rate their cur-
rent health as good (71%) and were not currently trying to
conceive (91%) (Table 2).
Logistic regression analysis was performed to determine if
there was a difference in any of the stratified demographic
variables for the survey questions. Significant differences
were associated with gender and highlighted that male re-
sponders appear to have more negative views of SMA
(Table 3). Using the female responders as the reference, logis-
tic regression suggests that males with SMA did not think
people with SMA could live fulfilling lives (OR: 0.26;
p = 0.02; Table 3); they also thought SMA causes people to
suffer (OR 3.89 l p = 0.004; Table 3) and that it would not be a
loss to society if fewer people with SMAwere being born (OR
0.38; p = 0.04; Table 3).
We have previously shown that adults with Type II have a
more positive view on the disease than adults with Type III
(Boardman et al. 2017; Table 4). Similar differences to those
reported between Types II and III were also seen between
adults with Type II and IV SMA (Table 4). More Type II than
Type IV adults thought that people with SMA could live ful-
filling lives (93% v 67%, respectively; p = 0.01; Table 4).
Conversely, fewer Type II than Type IV adults agreed that
SMA causes people to suffer (26% v 67%, respectively;
p = 0.005; Table 4). For both of these questions, there were
no significant difference between adults with Type III and IV
(Table 4). However, the most interesting differences were as-
sociated with perceived heightened intelligence in people with
SMA, for which there seemed to be an inverse relationship
between the clinical severity of disease the responders had,
and their agreement that SMA causes heightened intelligence
(Type II: 74%, Type III: 35%, Type IV: 8%; Table 4).
Attitudes Towards pre-Conception Genetic Screening
While 70% of the combined cohort supported pre-conception
genetic screening, only 54% of Type IVadults were in favour
of this form of screening (Table 5); this was lower than both
Type II adults (63%) and Type III adults (87%); the difference
between the Type III and Type IV adults was significant
(p = 0.006; Table 5), highlighting diagnosis of SMA in adult-
hood may impact the view screening.
The only other statistical differences between the differed
sub-types have previously reported (Type II v III; Table 5).
Interestingly, the majority Type IV adults: 1) did not think
identifying carriers would alter their choice of reproductive
partners (58%- this figure was higher than for Type II (48%)
and Type III (39%) adults, although the differences were not
significant; Table 5); 2) did not think carriers would be
stigmatised; and 3) did believe it would reduce the number
of terminations; did believe it would increase SMA awareness
in the general population. The lack of significance between
the Type II v Type IVand Type III v Type IV for the majority
of questions, when there is a significant difference between
the Type II v Type III, highlights that the reviews of the Type
IV patients are moderate- falling (in general) between those
held by the other Types.
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Attitudes Towards Prenatal Screening
Comparing the support for prenatal screening highlighted no
significant differences between Type IV adults and the other
two forms (Type II v IV: 52% v 75%, p = 0.08; Type III v IV:
81% v 75%, p = 0.61; Table 6). Compared to the other sub-
groups, more Type IVadults supported prenatal screening that
both pre-conception screening (Table 5) and newborn screen-
ing (Table 7).
Compared with Type II adults, a larger percentage of Type
IV adults thought prenatal screening would prevent suffering
(55% v 22%, p = 0.01; Table 6) and that screening was im-
portant even if the type could not be determined (71% v 44%,
p = 0.02; Table 6). There were also fewer Type IVadults who
Table 2 Demographic data for SMA Screening Survey (UK) Participants
Characteristics Adults with SMA(AwS) Statistical Comparison*
All Type II (n = 27) Type III (n = 31) Type IV (n = 24) Type II v III/IV (n = 55) Type II v III/IV
Gender-no. (%) 0.06
Male 37 (45%) 8 (30%) 14 (45%) 15 (63%) 29 (53%)
Female 45 (55%) 19 (70%) 17 (55%) 9 (37%) 26 (47%)
Education 0.0002
Degree or Higher 28 (34%) 17 (63%) 5 (16%) 6 (25%) 11 (20%)
Other 54 (66%) 10 (37%) 26(84%) 18 (75%) 44 (80%)
Religious 1.0
Yes 45 (55%) 15 (56%) 17 (55%) 13 (54%) 30 (55%)
No 37 (45%) 12 (44%) 14 (45%) 11 (46%) 25 (45%)
Do you have children 0.03
Yes 42 (51%) 9 (33%) 18 (58%) 15 (63%) 33 (60%)
No 40 (49%) 18 (67%) 13 (42%) 9 (37%) 22 (40%)
How would you rate you current health 0.6
Good 24 (29%) 9 (33%) 10 (32%) 5 (21%) 15 (27%)
Other 58 (71%) 18 (67%) 21 (68%) 19 (79%) 40 (73%)
Are you and parent currently trying to get pregnant 0.21
Yes 7 (9%) 4 (15%) 1 (3%) 2 (8%) 3 (5%)
No 75 (91%) 23 (85%) 30 (97%) 22 (92%) 52 (95%)
Table 3 Comparison of the
views of adults with SMA on the
impact of SMA
Adults with SMA Statistical
Comparison
Adults with SMA
(all; n = 82)
Type II
(n = 27)
Type III
(n = 31)
Type IV
(n = 24)
Type II v III/IV
(n = 55)
Type II v III/IV
Question P Value
People with SMA can live a fullfilling life 0.04
Agree 65 (79%) 25 (93%) 24 (77%) 16 (67%) 40 (80%)
Other 17 (21%) 2 (7%) 17 (23%) 8 (33%) 15 (20%)
Having SMA causes people to suffer 0.001
Agree 43 (52%) 7 (26%) 20 (65%) 16 (67%) 36 (65%)
Other 39 (48%) 20 (74%) 11 (35%) 8 (33%) 19 (35%)
People with SMA have heightened Intelligence <0.0001
Agree 33 (40%) 20 (74%) 11 (35%) 2 (8%) 13 (24%)
Other 49 (60%) 7 (26%) 20 (65%) 22 (92%) 42 (74%)
People with SMA are well supported by society 0.51
Agree 12 (15%) 5 (19%) 5 (16%) 2 (8%) 7 (13%)
Other 70 (85%) 22 (81%) 26 (84%) 22 (92%) 48 (87%)
Quality if life varies across the different type of SMA 1.0
Agree 74 (90%) 25 (93%) 29 (94%) 20 (83%) 49 (89%)
Other 8 (10%) 2 (7%) 2 (6%) 4 (17%) 6 (11%)
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thought that it would be a loss to society if fewer people with
SMAwere born (26% v 67%, p = 0.002; Table 6). In compar-
ison, there was no significant difference between responses
from Type III and Type IVadults for any of the prenatal ques-
tions. This demonstrates that the Type II adults appear to have
the most negative views on prenatal screening, which is
underscored by their positive views of the disease and its
impact. These positive views do not appear to be widely held
in the adults living with the milder forms of the disease.
Attitudes Towards Newborn Screening
The majority of responders were in favour of newborn screen-
ing (74%; Table 7), with no significant difference between the
levels of support in Type II adults (78%), Type III adults
(77%) and Type IV adults (67%) (Table 7). When the re-
sponses were assessed together, there was more support
among adults with SMA for newborn screening than either
pre-conception or prenatal screening (74% v 70% v 70%;
Table 4, 5, 6 and 7). The only significant difference related
to whether newborn screening would extend the life expectan-
cy of affected children: significantly more Type II adults
thought this was the case compared with Type IV adults
(74% v 29%, respectively; p = 0.001; Table 7). In all other
questions, there were good levels of agreement; adults from all
sub-types believed newborn screening would allow early en-
rolment on clinical trials, would mitigate the effects of a late
diagnosis and would enable all parents to make informed de-
cisions about subsequent pregnancies (Table 7). Importantly,
all groups agreed that diagnosis at birth was important, even if
the type of SMA could not be determined (Table 7). This
highlighted a significant difference in attitudes to prenatal
and newborn screening in adults with Type II (Tables 6 and
7). This suggests that for adults with Type II SMA, issues
around selective pregnancy termination are the most troubling
aspect of SMA screening.
Qualitative Results
In total, 15 adults with SMA participated in an in-depth
interview (see Table 1). Their experiences with SMA as
well as their reproductive decisions and attitudes were
explored.
SMA Type and Views on Screening: ‘I Just don’t see SMA
as a big Deal’
Screening for SMA emerged from the qualitative analysis as a
divisive topic, which elicited a range of viewpoints. As
highlighted by the quantitative findings, adults diagnosed with
Type II SMAwere more critical of screening than their coun-
terparts with Types III and IV. This finding was also reflected
in the qualitative dataset. All but one of the eight participants
with Type II SMA expressed significant concerns about what
Table 4 Views of Adults with
SMA on Pre-Conception Genetic
Screening (PCGS)
Adults with SMA Statistical
Comparison
Adults with SMA
(all; n = 82)
Type II
(n = 27)
Type III
(n = 31)
Type IV
(n = 24)
Type III/IV
(n = 55)
Type II v
Type III/IV
Question P Value
Identifying SMA carries before pregnancy would affect people’s choice of reproductive partners 1.0
Agree 43 (52%) 14 (52%) 19 (61%) 10 (42%) 29 (53%)
Other 39 (48%) 13 (48%) 12 (39%) 14 (58%) 26 (47%)
Identifying SMA carries in the general population will lead to carriers feeling stigmatised 0.47
Agree 34 (41%) 13 (48%) 10 (32%) 11 (46%) 21 (38%)
Other 48 (59%) 14 (52%) 21 (68%) 13 (54%) 34 (62%)
Identifying SMA carries before pregnancy will reduce the number of SMA-associated
terminations
0.07
Agree 57 (70%) 15 (56%) 25 (81%) 17 (71%) 42 (76%)
Other 25 (30%) 12 (44%) 6 (19%) 7 (29%) 13 (24%)
Identifying SMA carries in the general population will increase awareness of SMA as a condition 0.11
Agree 69 (84%) 20 (74%) 29 (94%) 20 (83%) 49 (89%)
Other 13 (26%) 7 (26%) 2 (6%) 4 (17%) 6 (11%)
Pre-conception screening is a form of social engineering 0.16
Agree 36 (44%) 15 (56%) 9 (29%) 12 (50%) 12 (38%)
Other 46 (56%) 12 (44%) 22 (71%) 12 (50%) 34 (625%)
I would support a pre-conceptoin genetic screen for SMA 0.44
Agree 57 (70%) 17 (63%) 27 (87%) 13 (54%) 40 (73%)
Other 25 (30%) 10 (37%) 4 (13%) 11 (46%) 15 (27%)
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screening would mean for adults like themselves currently
living with SMA, as well as broader concerns about the im-
plications that a permissive attitude towards genetic screening
would have for other disabled people and wider society.
Catalina has Type II SMA, is 35 years old, living indepen-
dently (assisted by support workers) and works part-time. She
was diagnosed with SMA at the age of 18 months and,
despite initially learning to walk, became a fulltime
wheelchair user at the age of two. Catalina was very
clear in her views that genetic screening was a practice
that she could not support:
Oh god yeah, I just hate the idea of it [genetic screen-
ing], hate it. I mean it’s like genocide for the modern era
isn’t it? It’s portrayed as this sophisticated and progres-
sive new thing, this wonderful development and ‘isn’t it
great that we have all this new technology?’, but in
reality all they’re doing is bumping the babies off, aren’t
they? You know, what’s progressive about that?...[…]…
I’m very concerned about it, yes, because it shows you
really what this society thinks about disabled people.
[Catalina, 35, Type II]
For adults with Type II SMA who were living fulfilling,
independent and productive lives, it is not difficult to see how
screening did not align with their own personal goals, which
often focused on physical and attitudinal barrier removal and
equal participation in society. Indeed, perceptions of SMA-
and what sort of life was perceived possible for a person di-
agnosed with SMA- were critical to understanding screening
attitudes across all types and experiences of SMA.
Amy is in her early thirties and, like Catalina, was diag-
nosed with SMAType II at an early age (28 months), coming
to rely on a wheelchair for mobility from the age of three. At
the time of interview, Amy was working full time and living
with her husband. When asked about her perceptions of both
SMA and screening, Amy responded in the following way:
Table 5 Views of Adults with
SMA on Prenatal Genetic
Screening (PNGS)
Adults with SMA
(all; n = 82)
Type II
(n = 27)
Type III
(n = 31)
Type IV
(n = 24)
Type III/IV
(n = 55)
Type II v Type
III/IV
Question P Value
Identifying SMA in pregnancy would lead to fewer people with SMA being born who could
live fulfilling
0.33
Agree 51 (62%) 19 (70%) 18 (58%) 14 (58%) 32 (58%)
Other 31 (38%) 8 (30%) 13 (42%) 10 (42%) 23 (42%)
Screening for SMA in pregnancy would enable everyone to make informed decisions 0.24
Agree 65 (79%) 19 (70%) 26 (84%) 20 (83%) 46 (84%)
Other 17 (21%) 8 (30%) 5 (16%) 4 (17%) 9 (16%)
Screening for SMA in pregnancy will prevent unnecessary suffering 0.009
Agree 35 (43%) 6 (22%) 17 (55%) 12 (50%) 29 (53%)
Other 47 (57%) 21 (78%) 14 (45%) 12 (5%) 26 (47%)
Screening for SMA in pregnancy will raise awareness of the condition in the general
population
0.13
Agree 66 (80%) 19 (70%) 28 (90%) 19 (79%) 47 (85%)
Other 16 (20%) 8 (30%) 3 (10%) 5 (21%) 8 (15%)
It would be a loss to society to have fewer people with SMA coming into the world 0.0006
Agree 32 (39%) 18 (67%) 8 (26%) 6 (25%) 14 (25%)
Other 50 (61%) 9 (33%) 23 (74%) 18 (75%) 41 (75%)
It would be difficult for pregnant couples to refuse screening for SMA during pregnancy 0.79
Agree 25 (30%) 9 (33%) 7 (23%) 9 (38%) 16 (29%)
Other 57 (70%) 18 (67%) 24 (77%) 15 (62$) 39 (71%)
Screening for SMA in pregnancy is useful even if the type of SMA can bot be determined 0.01
Agree 52 (63%) 12 (44%) 22 (71%) 18 (75%) 40 (73%)
Other 30 (37%) 15 (56%) 9 (29%) 6 (25%) 15 (27%)
Termination of milder forms of SMA is unfortunately necessary to reduce the number of
children with severe SMA being born
0.09
Agree 19 (23%) 3 (11%) 10 (32%) 6 (25%) 16 (29%)
Other 63 (77%) 24 (89%) 21 (68%) 18 (75%) 39 (71%)
I would support a prenatal screening programme for SMA 0.02
Agree 57 (70%) 14 (52%) 25 (81%) 25 (75%) 43 (78%)
Other 25 (30%) 13 (48%) 6 (19%) 6 (25%) 12 (22%)
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You see I don’t agree with any sort of screening for
SMA, but I guess that’s because I just don’t see SMA
as a big deal. I mean….well ok, yes, it’s a big deal- I
can’t walk and I have a lot of weakness in my arms that
limits me in some ways, but other than that, it hasn’t
held me back at all. I don’t think my life would have
turned out much different if I hadn’t had it, if you see
what I mean. So I suppose I just…I just think there are
far worse things you can have in life than SMA, you
know? […]… I have a friend who’s ill with depression,
she’s had it for years, and to me, she struggles with that
so much more than I do. But I don’t think we’d be
having this conversation about screening for depression
would we? I don’t think it would be seen as acceptable
Table 6 Views of Adults with
SMA on Newborn Genetic
screening (NGS)
Adults with SMA Statistical
Comparison
Adults with SMA
(all; n = 82)
Type II
(n = 27)
Type III
(n = 31)
Type IV
(n = 24)
Type III/IV
(n = 55)
Type II v
III/IV
Question P Value
Identifying SMA at birth would lead to better support for children and families 0.17
Agree 76 (93%) 27 (100%) 27 (87%) 22 (30%) 49 (89%)
Other 6 (7%) 0 (0%) 4 (13%) 2 (8%) 6 (11%)
Identifying SMA at birth would extend the life expectancy of SMA children 0.004
Agree 41 (50%) 20 (74%) 14 (45%) 7 (29%) 21 (50%)
Other 41 (50%) 7 (26%) 17 (55%) 17 (71%) 34 (62%)
Identifying SMA at birth and not during pregnancy removes parents’ ability to make informed
decisions about bringing SMA children into the world
0.48
Agree 39 (48%) 11 (41%) 16 (52%) 12 (50%) 28 (51%)
Other 43 (52%) 16 (59%) 15 (48%) 12 (50%) 27 (49%)
Identifying SMA before symptoms emerge will prevent families and children enjoying life while
they are symptom free
0.46
Agree 26 (32%) 7 (26%) 9 (29%) 10 (42%) 19 (35%)
Other 56 (68%) 20 (74%) 22 (71%) 14 (58%) 36 (65%)
Identifying SMA at birth will help research by enabling more children to enrolled into clinical
trials early on
1.0
Agree 63 (77%) 21 (78%) 21 (68%) 21 (88%) 42 (76%)
Other 19 (23%) 6 (22%) 10 (32%) 3 (12%) 13 (24%)
Identification of SMA at birth would interfere with the early bonding process 0.51
Agree 12 (15%) 5 (19%) 4 (13%) 3 (12%) 7 (13%)
Other 70 (85%) 22 (81%) 27 (87%) 21 (88%) 48 (87%)
Identification of SMA at birth would the diagnosis easier for parents to accept 0.47
Agree 36 (44%) 10 (37%) 15 (48%) 11 (46%) 26 (47%)
Other 46 (56%) 17 (63%) 16 (52%) 13 (54%) 29 (53%)
Identifying SMA at birth would spare the difficulties associated with finding a diagnosis for a
child later on
0.42
Agree 61 (74%) 22 (81%) 22 (71%) 17 (71%) 39 (56%)
Other 21 (26%) 5 (19%) 9 (29%) 7 (29%) 16 (29%)
Identifying SMA at birth is important, even if the type can not be determined 0.57
Agree 64 (78%) 20 (74%) 25 (81%) 19 (79%) 44 (80%)
Other 18 (22%) 7 (26%) 6 (19%) 5 (21%) 11 (20%)
Identifying SMA at birth is important because it will enable parents to make informed decisions
about future pregnancies
1.0
Agree 67 (82%) 22 (81%) 26 (84%) 19 (79%) 45 (82%)
Other 15 (18%) 5 (19%) 5 (16%) 5 (21%) 10 (18%)
It is unthical to screen newborns for conditions that have no effective treatment 1.0
Agree 8 (10%) 3 (11%) 2 (6%) 3 (12%) 5 (9%)
Other 74 (90%) 24 (89%) 29 (94%) 21 (88%) 50 (91%)
I would support a Newborn screening programme for SMA 0.78
Agree 61 (74%) 21 (78%) 24 (77%) 16 (67%) 40 (73%)
Other 21 (26%) 6 (22%) 7 (23%) 8 (33%) 15 (27%)
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Views of Adults with SMA on Genetic Screening
to screen out depressives, would it? [laughs] So yeah… I
just don’t really get it.
[Amy, 35, Type II]
Amy’s contrast between depression, which she terms an
‘illness’ and her SMA, which she accepts as an integral aspect
of her being (and not one that has limited her life) was a
striking theme across her interview. For Amy, her non-
support of screening was entirely grounded in her view of
SMA, which, she argues, is not a ‘big deal’.
De Wolfe (2002) in her attempt to demarcate the blurry
boundaries between ‘illness’ and ‘disability’, as they emerge
in the disability rights and medical sociology literature, has
argued that a key difference between the two concepts lies in
the accommodation of suffering. While, for political ends,
disability rights supporters have traditionally been eager to
separate out the experiential reality of suffering from
definitions of impairment and disability, De Wolfe (2002) ar-
gues that such a severance overlooks the needs and rights of
the chronically ill, for many of whom ‘illness’ necessarily, and
by definition, causes suffering (p. 225).
This presentation of SMA as a ‘disability’ as opposed to an
‘illness’ was in stark contrast to the accounts of adults with
Types III and IV SMA, who, as a group, expressed consider-
ably more ambivalence about the reality of living with SMA
than adults with Type II.
Virginia is in her late 40s and was diagnosed with Type IV
SMA at the age of 30. While she believes the onset of her
symptoms was triggered by the birth of her child (Paul) at the
age of 22, it took 8 years (and many misdiagnoses) to finally
have her diagnosis confirmed. Now at the age of 48, Virginia
has given up full time work due to fatigue and is only able to
walk short distances. Her son, Paul, now 26, has not under-
gone testing for SMA and is not displaying symptoms. He
undertakes regular care work for his mother following the
breakdown of her marriage. Virginia described her views in
the following way:
Well, for me, when I had Paul, I didn’t even realise that I
had SMA, so I didn’t have any screening for him, but it’s
something I feel very strongly about now…. that if I
could go back and do it all again [pregnancy] I would
absolutely [screen]. I think it’s really important to know
what you’re getting into, and for me, SMA is a big no-
no. I’m not saying I have a terrible life, but it’s definitely
gone downhill since I got the SMA. It had a major part
to play in the breakdown of my relationship with Paul’s
father. I also used to work in [shop] fulltime, but it just
got to the point that I couldn’t be on my feet for long
periods, and I was devastated to lose that job. And you
know, it isolates you, not working, and not being able to
get out and about like you used to. So if I’d known I had
this condition, there’s no way I’d have risked Paul
getting it. To be fine up to a point then go downhill,
it’s cruel really, and not something I’d want for my child.
[Virginia, 48, Type IV]
Informed by her experiences of SMA, Virginia’s sense of
‘genetic responsibility’ (Kenen 1994) was clearly expressed in
her reaction to screening technologies. In contrast to Amy-
and in spite of having a milder clinical diagnosis than Amy-
life with SMA was, for Virginia, punctuated by periods of
major loss and decline and instilled in her a sense of moral
obligation to prevent transmission to her offspring. Indeed,
shame, guilt and blame for a parents’ genetic endowment have
been widely observed within the literature in relation to heri-
table conditons (Dragonas 2001; Hallowell et al. 2006; Reed
2009) and the majority of parents who participated in this
study reported some degree of sensed culpability for the con-
dition in their family. Virginia’s negative experiences of SMA
heightened her sense of obligation. Indeed, she was already
married, a parent and in a physically demanding job by the
time her muscle weakness onset, a situation which she stated
both caused her considerable anxiety (regarding the potential
transmission of the condition to her son) as well as the even-
tual loss of her much-loved career and deterioration of her
marriage. Unlike Amy, who was able to make life choices
around her disability from the outset, the unanticipated onset
of a serious neuromuscular condition meant a significant re-
formulation of Virginia’s day-to-day life.
Such experiences were not uncommon amongst other peo-
ple diagnosed with later onset forms of SMA; all but one of
whom described experiencing significant losses (career, par-
enting experiences, significant relationships, hobbies) after the
onset of their condition. Locock et al. (2009), using Bury’s
(1982) theory of ‘biographical disruption’, have argued that
people living with degenerative neuromuscular disease must
engage in continual cycles of ‘biographical disruption’ (as
their disease progresses and they lose function), followed by
periods of ‘biographical repair’, during which they attempt to
adjust to their new circumstances and abilities. References to
these cycles of crisis and then re-adjustment also appeared
across the accounts of adults with later onset forms of SMA
and has also been noted in the limited literature on the expe-
riences of adults with Type III SMA (Lamb and Peden 2008;
Ho et al. 2016). For Virginia, SMA was experienced as a
disruptive intrusion into her life, and one that required her to
make continual adjustments. This conceptualisation logically
led her to view SMA as something that she would want to
prevent occurring in her child’s life.
SMA, Identity and Screening: ‘I Want My Life- Just
without the SMA’
For many adults with late onset forms of SMA, the changes
brought about through the onset of their condition not only
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had a significant impact on the circumstances of their daily
lives, but also on their sense of personal identity. Ryan was in
his fifties at the time of his interview, having been diagnosed
with Type IV SMA in his early thirties. Prior to the onset of his
condition, Ryan had worked as a martial arts coach.While still
involved with the martial arts and fitness industry, Ryan de-
scribed his disappointment at recently having to take on less
physically demanding roles. While still able to walk at the
time of interview, Ryan described now using walking aids
(crutches) for longer distances and sometimes a wheelchair.
Ryan described his experiences in the following way:
To be honest, the biggest impact [of SMAType IV] for
me has been in terms of how I feel about myself- how I
see myself. My muscle mass has decreased significantly
since then [onset of SMA], and when I go to the gym
now I can’t look at myself in the mirror because I
just….I don’t recognise who I see…[…]….I had to give
[colleague] a lift home the other day and he saw my
crutches in the car, and I felt mortified. Mortified that
this is who I’ve become. He was fine about it, but I find
it very hard to admit…that I’ve got a disability.
[Ryan, 54, Type IV]
It has long been argued that men’s experiences with dis-
ability are at odds with social norms of masculinity with its
emphasis on ‘virility, autonomy and independence’ (Asch and
Fine 1988). However, as Shuttleworth et al. (2012) highlight,
proponents of this argument overlook the various points of
intersectionality between impairment experiences and
masculinities. Indeed, for Ryan, the onset of SMA forced
him to reconcile his new disabled identity, ‘this is who I’ve
become now’with his identity as a previously able-bodied and
fit man.
Being able to separate out SMA from one’s sense of per-
sonal identity appeared particularly critical to understanding
differences in screening attitudes amongst adults with differ-
ent types of SMA.While adults with Type II spoke of SMA as
constituting part of their very being, ‘it’s just who I am’
(Amy), adults with later onset forms of SMA (Types III and
IV) were more likely to view SMA as external to their sense of
self, which in turn impacted their views of screening. Ryan
went on to describe his views of screening for SMA in the
following way:
You see, I see screening as completely necessary be-
cause I don’t hold much faith in being able to cure it,
so the only way to beat this thing is through screening. I
know you will get some who will say ‘yes but you can
still have a reasonable life with this condition’, and yes
you can, but life shouldn’t be about just ‘managing’
should it? Just getting by? You know, I manage, I get
by, but a life without this condition would have been
preferable. And to me, that’s the point. That’s why we
need screening to happen, I want my life- just without
SMA.
[Ryan, 54, Type IV]
As Ryan’s account exemplifies, viewing SMA as external
to one’s sense of self enabled a conceptualisation of screening
as a process capable of eradicating a disease, rather than a
particular sub-group of people who have that disease. This
dislocation between sense of self and SMA emerged strongly
in the accounts of those adults who supported screening, and
yet was resolutely absent for participants like Catalina, for
whom screening was likened to genocide, designed to eradi-
cate not the incidence of a condition, but a particular ‘kind’ of
person.
Discussion
This study is the first to describe and compare the views of
adults with different types of SMA (II-IV) towards three po-
tential population level screening programmes for SMA (pre-
conception, prenatal and newborn). The analysis has
underscored significant differences between adults with
Type II SMA and their counterparts with SMATypes III and
IV, a finding which has been alluded to in other studies of
adults with SMA (e.g. Kruitwagen-van Reenen et al. 2016;
Jeppesen et al. 2010). Indeed, despite participants with Type II
experiencing the severest clinical presentation and earliest on-
set of SMA represented within this sample, adults with Type II
reported far more positive views of the condition than those
with milder presentations. More severely affected participants
were more likely to report high quality of life, to refute the
claim that SMA necessarily involves suffering and were more
likely than their less severely affected counterparts to see pos-
itive attributes associated with SMA, such as heightened in-
telligence (Von Gontard et al. 2002).
Given this relative positivity displayed by adults with Type
II SMA, it is perhaps unsurprising that, as a group, they were
more supportive of newborn screening (which would not alter
the number of children being born with SMA) compared to
prenatal screening (which would potentially increase the num-
ber of SMA-related terminations). Indeed, the qualitative and
quantitative data both provided clear evidence that the lower
levels of support for screening amongst people with Type II
SMA stemmed from a fundamental conviction that life with
SMA is of considerable value, and consequently that it would
be of detriment to have less people with SMA being born.
However, it is important to bear in mind when interpreting
these data that in spite of this conviction, most still agreed that
a pre-conception (63%) or prenatal programme (52%) should
be available to the general population, even if they might not
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make use of genetic technologies within their own reproduc-
tive decisions.
These findings are supported by the (somewhat limited)
literature exploring the views of affected families and individ-
uals towards population-level genetic screening, where such
screening is broadly supported in spite of ambivalence to-
wards their usage (Maxwell et al. 2011; Skinner et al. 2003).
Jeppesen et al. (2010) have argued that due to the early
onset of Type II, families with affected children are able to
access childhood disability services which are typically more
substantial in their provision than those available for disabled
adults (Campbell et al. 2016). Early supportive environments
have been described as critical to the installation of an endur-
ing positive self-image amongst children with disabilities
(Hauser-Cram et al. 2001). Adults with Type II SMA who
were interviewed for this study emphasised the importance
of these early positive experiences. In particular, the critical
role of parents in supporting the transition to adulthood was
emphasised. The introduction of the Equality Act (2010) and
the protection of the rights of disabled people to work, have
children and otherwise participate in society has also meant
that opportunities for adults with all types of SMA have im-
proved considerably in recent years. Many such adults are
now entering higher education, living independently (through
the use of self-directed care plans), undertaking paid employ-
ment and becoming parents themselves (Jeppesen et al. 2010).
In spite of this, however, most adults with SMAType II (81%)
reported feeling unsupported by wider society, suggesting that
their positivity about SMA cannot solely be attributed to im-
proved social and environmental arrangements. Rather, it ap-
peared to be inextricably bound up with how they viewed and
experienced their impairment and how they incorporated it
within their lives.
Adults affected by the clinically milder forms of SMA
(Types III and IV) were more likely to hold negative views
of the condition and to more strongly support the forms of
screening with the potential to reduce the number of births
of SMA children (pre-conception and prenatal genetic screen-
ing). Adults with these forms of SMA typically have normal
gross motor development prior to the onset of symptoms,
which in some instances may not start until late middle-age.
Kruitwagen-Van Reenen et al. (2016) have argued that dis-
crepancies between self-reported quality of life across SMA
types are due primarily to the delayed onset of the condition in
its milder forms. Becoming disabled in early-mid adulthood is
a very different experience to being born with the condition,
with the onset of the condition invariably involving a re-
calibration of an individual’s hopes, dreams and expectations
of their life (Locock et al. 2009).
Writing on the concept of cure, Tom Shakespeare (2006)
has argued that different ‘impairment groups’ have highly
contrasting views on the possible amelioration of their condi-
tion, depending, largely, on the nature of their experience with
that condition. Those people living with relatively fixed and/
or congenital impairments, he argues, are typically more
accepting and well-adjusted to them than people whose con-
ditions onset later in life, or whose symptoms fluctuate and/or
deteriorate (Shakespeare 2006: 106). This argument is sup-
ported by studies within the psychological and rehabilitation
literature, where similar differences in attitudes have been ob-
served between people born with their condition and those
who acquire it (for example through traumatic spinal cord
injury) with the latter group more fervently pursuing treat-
ments and cure (e.g. Bogart 2014; Bogart et al. 2012; Hahn
and Belt 2004).
It has been postulated that personal identification with the
condition, and the adoption of a ‘disabled identity’ (Watson
2002) is critical to understanding this phenomenon. Indeed,
people born with their impairments are more likely to view it
as an integral aspect of their personhood (having always been
there), which in turn, invariably impacts their views towards
its ammeloriation, whether this be through cure or through
genetic screening programmes (Kruitwagen-van Reenen
et al. 2016). For those who strongly identified with their im-
pairment, it is not difficult to see how the practice of screening
could be interpreted as a negative evaluation of their own lives
(Sinason 1992). As Edwards (2004) has argued, the
‘expressivist objection’, that is, the hurt and offence that many
disabled feel towards the practices of prenatal testing and se-
lective pregnancy termination (Parens and Asch 2000), only
makes sense if the disability is considered to be ‘identity con-
stituting’ in some way. Indeed, similar objections are typically
not made in relation to other areas of preventative medicine,
such as childhood vaccinations (Malek 2010).
Differences in the degree of personal identification with
SMA was also evident in the data relating to health. It is
noteworthy that when compared to adults with Type II, par-
ticipants with Types III or IV were more likely to rate their
health as poor. This finding might be considered surprising
given that people with Type II SMA are (clinically) more
severely affected by the disease; they are more likely to suffer
chest infections and respiratory complications, are more likely
to need nutritional support and surgical interventions for or-
thopaedic complications (such as Scoliosis and join contrac-
tures) than people diagnosed with SMATypes III or IV (Wang
et al. 2007). However, this finding can be explained by the
observation that adults with Type II SMA separate out their
(relatively static and ever-present) disability from their under-
standing of health and illness, a phenomenon which has been
referred to as ‘response shift’ (Kruitwagen-van Reenen et al.
2016: 5). As adults with Types III and IV SMA are likely to
have spent a large proportion of their lives symptom-free, the
SMA-onset is more likely to be experienced as a ‘threat’ to
their health and wellbeing (Shakespeare 2006: 107), rather
than entirely separate from it, leading to perceptions of SMA
as an ‘illness’ rather than disability, and consequently as
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something in need of correction or treatment (Boardman
2013).
In conclusion, this study has revealed that the type of SMA
affecting a person, and consequently the nature of their expe-
riences with that impairment, has the greatest influence on
genetic screening (non)support than any other factor (age,
gender, educational background, religion etc.), with support
for genetic screening declining the more severely affected a
person is. It has been argued that personal identification with,
and acceptance of a disabled identity (which is in turn associ-
ated with an earlier onset of the condition and a relatively
static disease trajectory) is key to understanding this finding.
While this concept has previously been explored in relation to
the notion of cure (Shakespeare 2006; Hahn and Belt 2004),
this study underscores the need to transfer this analysis and
understanding of the experiential realities of the lives of dis-
abled people to the arena of selective reproduction. As geno-
mic medicine advances, ability to detect (and consequently
screen for) genetic conditions is now far outstripping ability
to treat and cure them, rendering the perspectives of people set
to be directly affected by this expanded screening (people with
genetic disabilities themselves) ever more important in deter-
mining, and implementing, the screening agenda.
Practice Implications
This study emphasises the need of genetic counselors to be
attentive to the experiential dimensions of impairment and
personal identification with genetic disease in counseling con-
texts. Disabled people identify more or less with their impair-
ment for a range of reasons, and age of onset/severity are key
components of this relationship that may have serious impli-
cations for reproductive attitudes. People with disabilities
have long been understood as having a fraught relationship
with genetic medicine more broadly (e.g. Catalina within this
study), with the association with eugenics posing particular
challenges (Peterson 2012). Identity politics are key to under-
standing these tensions, and this study highlights the need for
open dialogue between genetic counselors and disabled pa-
tients surrounding the nature, meaning and significance of
their impairment experiences and how these relate to decisions
to use, or not use, genetic technologies.
As capacity to offer screening for ever-larger numbers of
rare genetic conditions expands, people living directly with
these conditions have an increasing role to play in the con-
comitant decisions around which conditions should, and
which should not, be included on such expanded screening
panels. Representing the ‘best experts’ (Petersen 2006) on
their own conditions, it is critical that policymakers, clinicians
and scientists both value, and make use of, the experiential
knowledge of disabled people to inform such decisions.
Indeed, as this study highlights, reliance on clinical disease
severity to determine a condition’s suitability for inclusion on
genetic screening panels (e.g. Leo et al. 2016) may not ade-
quately target those conditions which have the largest negative
impact on a person’s day-to-day life.
Indeed, disabled people’s experiences are also relevant
to the micro-level decisions made by members of the gen-
eral population undergoing screening (Shakespeare 2005).
Involving people currently living with the screened-for
conditions in the education and training of the clinicians
who will deliver screening (for example involving them in
the production of patient literature and facilitating contact
between prospective parents and those living with the
screened-for conditons as appropriate) is a key means
through which the experiential knowledge of disabled
people and their families can be utilised and valued in
screening contexts. Different online methods for convey-
ing these insights have been developed (Ahmed et al.
2007; Telling Stories 2007), however, further research is
warranted to explore the most effective and appropriate
means of delivering this information in the context of
high yield genetic screens.
Research Recommendations
Further research is warranted to explore how adults with
conditions that have contrasting presentations to SMA
(e.g. those involving chronic pain or behavioural/
cognitive symptoms), those that are treatable (e.g.
Haemophilia) or those which are early onset, but that
which can nevertheless significantly fluctuate or deterio-
rate from the outset (e.g. Cystic Fibrosis, Duchenne
Muscular Dystrophy) view the possibility of genetic
screening. Research is also required to explore the quan-
tity, nature and preferred mode of delivery of information
about the genetic conditions that can now be screened for
within the general population. While some of these con-
cerns are currently being addressed within studies explor-
ing consent processes for additional findings in genomic
sequencing studies (e.g. Cornelis et al. 2016), whether and
how information needs alter and fluctuate over the course
of reproductive decision-making has yet to be thoroughly
explored.
Study Limitations
Due to confidentiality and data protection issues, no iden-
tifiable data were asked of individuals who participated in
the SMA Screening Survey (UK), including IP addresses
(where the survey was completed online). This meant that
there was no mechanism in place to prevent an individual
completing multiple surveys. Moreover, there was no way
of verifying that the participant fitted the inclusion criteria
to participate in the survey. Participants were furthermore
accessed through a national support group, personal
Views of Adults with SMA on Genetic Screening
networks and a patient registry rather than neuromuscular
clinics, which may have introduced bias. Due to the very
poor prognoses associated with Type I SMA, the adults
with SMA who participated in this study were largely
affected with clinically milder forms of SMA which in-
variably will have altered their percetpions of the disease.
However, we feel that this sample bias does not negate the
value of the perspectives of more mildly affected adults,
and indeed, even in its milder forms, SMA is still a con-
dition with significant implications for those who live
with it.
A further potential source of bias within the sample
relates to parental status, with a higher number of parents
within the Type III and IV groups than Type II. This is in
spite of the increasing number of peope affected by Type
II SMA becoming parents overall (Pugh et al. 2000).
Parental status might have influenced perceptions of
screening amongst these more mildly affected adults as
they were more likely to have previously considered the
possibility of SMA in their own child
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